Mark Rogers-Evans

This inventor holds 85 USPTO granted patents and 18 published patent applications, plus 7 CIPO patents and 49 EPO patents, primarily in Cannabinoid Receptor Agonists (CPC class C07D413-14). Top assignees: Hoffmann-La Roche Inc., Remynd Nv, Basilea Pharmaceutica Ag. Active years: 1997-2022.

USPTO Granted Patents = 85 (Patent Applications = 18)

% Patents Active = 25.9

CIPO Patents = 7 (Patent Applications = 13)

EPO Patents = 49 (Patent Applications = 53)

Average Co-Inventor Count = 5.3

ph-index = 8

Forward Citations = 246(Granted Patents)

Forward Citations (Not Self Cited) = 189(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Ettingen, CH (1997 - 2001)
Binningen, CH (2002 - 2010)
Oberwil, CH (2008 - 2012)
Oberwil BL, CH (2008 - 2012)
Bottmingen, CH (2011 - 2020)
Basel, CH (2021 - 2022)

Company Filing History:

76 out of 5,020

Hoffmann-La Roche Inc.

Basilea Pharmaceutica Ag

where one patent can have more than one assignee

Years Active: 1997-2022

Loading Chart...

Areas of Expertise:

Cannabinoid Receptor Agonists

BACE1 Inhibitors

Pyridine Derivatives

Pyrazole Compounds

Pyridyl-Triazabicycles

Oxadiazole Compounds

Triazolo[4,5-D]Pyrimidines

Piperazine Thiazole Derivatives

Pyridine-2-Amides

Purine Derivatives

Pyrrolidin-3yl-Methylamine

Spiro Compounds

85 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11339120 - Phenyl derivatives as cannabinoid receptor 2 agonists (2022-05-24),

2. 11117903 - Pyridine derivatives (2021-09-14),

3. 10829500 - Pyridyl-triazabicycles (2020-11-10),

4. 10562869 - Oxadiazole compounds (2020-02-18),

5. 10414780 - Pyridyl-triazabicycles (2019-09-17),

6. 10308659 - Pyridine derivatives (2019-06-04),

7. 10227308 - Radiolabeled cannabinoid receptor 2 ligand (2019-03-12),

8. 10183946 - Triazolo[4,5-D]pyrimidines (2019-01-22),

9. 10047102 - Pyridyl-triazabicycles (2018-08-14),

10. 9920072 - BACE1 inhibitors (2018-03-20),

11. 9896438 - 2,2,2-trifluoroethyl-thiadiazines (2018-02-20),

12. 9808456 - Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease (2017-11-07),

13. 9750745 - 2,7-diazaspiro[3.5]nonane compounds (2017-09-05),

14. 9694012 - Pyrazol derivatives (2017-07-04),

15. 9617264 - 2,7-diazaspiro[3.5]nonane compounds (2017-04-11),

Title: Mark Rogers-Evans: Pioneering Inventor Pushing Technological Boundaries

Introduction:

Mark Rogers-Evans, a trailblazing inventor based in Bottmingen, CH, is renowned for his forward-thinking ideas and groundbreaking creations that have left a lasting impact on the world. With an impressive portfolio of 85 patents, he continues to push the boundaries of technology and innovation.

Latest Patents:

Rogers-Evans' latest patents showcase his innovative spirit:

1. Phenyl Derivatives as Cannabinoid Receptor 2 Agonists: The invention introduces a compound with potential medicinal uses, displaying his versatility in various fields.

2. Pyridine Derivatives: This patent underscores his expertise in pharmaceuticals, opening doors for new medicament discoveries.

Career Highlights:

Having worked at esteemed companies like Hoffmann-La Roche Inc. and Remynd NV, Rogers-Evans has honed his skills and expertise over the years. His impressive patent count is a testament to his dedication to advancing technology and science.

Collaborations:

Rogers-Evans has collaborated with esteemed professionals in the industry, such as Matthias Heinrich Nettekoven and Caterina Bissantz, in bringing innovative ideas to life. These collaborations have further fueled his creativity and drive for excellence.

Conclusion:

Mark Rogers-Evans stands as a beacon of innovation, continuously striving to push the boundaries of technology and invention. His contributions to the world of patents and inventions are invaluable, and his forward-thinking ideas continue to inspire generations to come.